Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 September 2009

Arch Dis Child. Published Online First: 15 June 2009. doi:10.1136/adc.2008.154377
Copyright © 2009 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.

Review

Adverse drug reactions in childhood: a review of prospective studies and safety alerts

Antonio Clavenna 1* and Maurizio Bonati 1

1 Mario Negri Institute for Pharmacological Research, Italy

* To whom correspondence should be addressed. E-mail: clavenna{at}marionegri.it.

Accepted 26 May 2009


Abstract

Objective: To assess the incidence of adverse drug reactions (ADRs) in the paediatric population and the safety alerts concerning children and adolescents issued by international drug regulatory agencies since 2001.

Methods: A bibliographic search was performed in the Medline and Embase databases for prospective studies published between January 2001 and December 2007 evaluating the ADR incidence in the paediatric population. Data were analysed by a random effect model. Moreover, the websites of 9 international drug regulatory agencies were searched with the aim to collect information on safety alerts concerning the paediatric population.

Results: A total of 8 prospective studies were evaluated, six of which concerned the ADR incidence in hospitalised children. The overall incidence of ADRs was 10.9% (95%CI 4.8-17.0) in hospitalised children and 1.0% (95%CI 0.3-1.7) in outpatient children. The rate of hospital admission due to ADRs was 1.8% (95%CI 0.4-3.2). The skin and gastrointestinal system were the organs most commonly affected and antibiotics were the drugs most commonly associated with ADRs.

Safety alerts in the paediatric population were retrieved for 28 drugs, 5 of which were psychotropic drugs and most of which were issued by the Food and Drug Administration (20 drugs).

For 12 drugs, warnings were published in the 2006-2007 period. Only for antidepressants were alerts issued by all the drug regulatory agencies.

Conclusions: To ensure safe and effective medicines for children, efforts are needed at different levels (governments, drug regulatory agencies, pharmaceutical industries, health care professionals, and parents). Collaborative regulatory initiatives, as the use of common warnings, can also contribute to a more rational use of drugs for children.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs